Once-weekly albiglutide in the management of type 2 diabetes: patient considerations

References

• RossSABreaking down patient and physician barriers to optimize glycemic control in type 2 diabetesAm J Med20131269 Suppl 1S38S4823953078
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2014Diabetes Care201437Suppl 1S14S8024357209
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia2012551577159622526604
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineGSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)Middlesex, UKGlaxo-SmithKline2014 Available from: http://www.gsk.com/media/press-releases/2014/gsk-receives-us-approval-for-once-weekly-type-2-diabetes-treatme.htmlAccessed April 29, 2014
   Google Scholar
• OuYCBloomMGrzegorzewskiKJPharmacokinetic and pharmacodynamic analysis of Albugon, a long-acting analog of glucagon-like peptide-1 in mice and monkeysAAPS Pharm Sci200355263
   Google Scholar
• BloomMBockJDuttaroyAAlbugon fusion protein: a long-acting analog of GLP-1 that provides lasting antidiabetic effect in animalsDiabetes Care200352A112
   Google Scholar
• BaggioLLHuangQBrownTJDruckerDJA recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasisDiabetes2004532492250015331566
   PubMed Web of Science ®Google Scholar
• TomkinGHAlbiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetesCurr Opin Mol Ther20091157958819806507
   PubMed Web of Science ®Google Scholar
• Victoza (liraglutide [rDNA origin] injection). Product informationPlainsboro, NJ, USANovo Nordisk2013
   Google Scholar
• Byetta (exenatide injection). Product informationPrinceton, NJ, USABristol-Myers Squibb Company2013
   Google Scholar
• PolonskyWHFisherLHesslerDBruhnDBestJHPatient perspectives on once-weekly medications for diabetesDiabetes Obes Metab20111314414921199266
   PubMed Web of Science ®Google Scholar
• BushMAMatthewsJEDe BoeverEHSafety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjectsDiabetes Obes Metab20091149850519187286
   PubMed Web of Science ®Google Scholar
• HolstJJDeaconCFVilsbollTKrarupTMadsbadSGlucagon-like peptide-1, glucose homeostasis, and diabetesTrends Mol Med20081416116818353723
   PubMed Web of Science ®Google Scholar
• SeinoYNakajiamaHMiyaharaHSafety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitusCurr Med Res Opin2009253049305719863477
   PubMed Web of Science ®Google Scholar
• MatthewsJEStewardMWDe BoeverEHPharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetesJ Clin Endocrinol Metab2008934810481718812476
   PubMed Web of Science ®Google Scholar
• RosenstockJReuschJBushMYangFStewartMAlbiglutide Study GroupPotential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized, controlled trial exploring weekly, biweekly, and monthly dosingDiabetes Care2009321880188619592625
   PubMed Web of Science ®Google Scholar
• SeinoYInagakiNMiyaharaHA randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitusCurr Med Res Opin Epub2014311
   Web of Science ®Google Scholar
• ReuschJStewartMPerkinsCHarmony 1 results at week 52 primary endpoint: once-weekly albiglutide vs placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin [abstract]Diabetes201362Suppl 1 Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0687e7c8-c97d-442b-92ec-ae505e051854&cKey=37d3bc28-d232-4cf4-969b-1f061e2de0de&mKey=89918d6d-3018-4ea9-9d4f-711f98a7ae5dAccessed April 29, 2014
   Google Scholar
• ReinhardtRNauckMAStewartMHarmony 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract] Available from: http://www.easdvirtualmeeting.org/resources/3898Accessed April 29, 2014
   Google Scholar
• AhrénBStewartMCirkelDYangFPerryCJohnsonSHarmony 3: 104 week efficacy of albiglutide compared with sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin [abstract]Diabetes201362Suppl 1 Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0687e7c8-c97d-442b-92ec-ae505e051854&cKey=536ec2d4-682a-49ce-80c1-bebcccae0900&mKey=89918d6d-3018-4ea9-9d4f-711f98a7ae5dAccessed April 29, 2014
   Google Scholar
• PratleyRStewartMCirkelDYeJPerryCCarrMCHarmony 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus [abstract]Diabetes201362Suppl 1 Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0687e7c8-c97d-442b-92ec-ae505e051854&cKey=7fda08fd-2fbc-41fa-8cff-7a5152a22488&mKey=89918d6d-3018-4ea9-9d4f-711f98a7ae5dAccessed April 29, 2014
   Google Scholar
• StewartMHomePYangFPerryCCarrMC52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: Harmony 5 study [abstract] Available from: http://www.easdvirtualmeeting.org/resources/3872Accessed April 29, 2014
   Google Scholar
• FonsecaVLAhrénBChowFOnce weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar glycaemic control with weight loss and less hypoglycaemia [abstract] Available from: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2978&sKey=880b06fe-7bc0-41d3-8a60-eccaaefd88cd&cKey=a4a9d018-2d00-4efe-a431-b34e39d6635c&mKey=2dbfcaf7-1539-42d5-8dda-0a94abb089e8Accessed April 29, 2014
   Google Scholar
• RosenstockJAhrénBChowFOnce-weekly GLP-1 receptor agonist albiglutide vs titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control with weight loss and less hypoglycemia [abstract]Diabetes201261Suppl 1A15A16
   Google Scholar
• PratleyRENauckMABarnettAHOnce-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (Harmony 7): a randomised, open-label, multicentre, non-inferiority Phase 3 studyLancet Diabetes Endocrinol2014228929724703047
   PubMed Web of Science ®Google Scholar
• LeiterLACarrMCStewartMJones-LeoneARYangFHandelsmanYHarmony 8: once weekly (QW) GLP1 agonist albiglutide (Albi) vs sitagliptin (Sita) in type 2 diabetes (T2D) pts with renal impairment (RI): week 26 results [abstract]Diabetes201362Suppl 1 Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=795037e5-ca6e-44a8-8b54-cfb1400cd733&cKey=92c0e7a1-9511-45d2-b37b-40dee04cc4e4&mKey=%7B89918D6D-3018-4EA9-9D4F-711F98A7AE5D%7DAccessed April 29, 2014
   Google Scholar
• ElashoffMMatveyenkoAVGierBElashoffRButlerPCPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesGastroenterology201114115015621334333
   PubMed Web of Science ®Google Scholar
• GargRChenWPendergrassWAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysisDiabetes Care2010332349235420682680
   PubMed Web of Science ®Google Scholar
• DoreDDBloomgrenGLWentenMA cohort study of acute pancreatitis in relation to exenatide useDiabetes Obes Metab20111355956621320263
   PubMed Web of Science ®Google Scholar
• Gonzalez-PerezASchliengerRGRodriguezLAAcute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort studyDiabetes Care2010332580258520833867
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetesSilver Spring, MD, USAUS Food and Drug Administration Available from: http://www.fda.gov/Drugs/DrugSafety/ucm343187.htmAccessed April 29, 2014
   Google Scholar
• European Medicines AgencyInvestigation into GLP-1-based therapies concludedLondon, UKEuropean MedicinesAgency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1Accessed April 29, 2014
   Google Scholar
• Bjerre KnudsenLMadsenLWAndersenSGlucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferationEndocrinology20101511473148620203154
   PubMed Web of Science ®Google Scholar
• Bydureon (exenatide extended-release for injectable suspension). Package insertPrinceton, NJ, USABristol-Myers Squibb Company2013
   Google Scholar
• Tanzeum (albiglutide). Product informationWilmington, DE, USAGlaxoSmithKline2014
   Google Scholar
• DarpoBZhouMMatthewsJAlbiglutide does not prolong QTc interval in healthy subjects: a thorough ECG studyDiabetes Ther Epub201428
   Web of Science ®Google Scholar
• BushMScottRWatanalumlerdPZhiHLewisEEffects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptivePostgrad Med2012124557223322139
   PubMed Web of Science ®Google Scholar
• MeierJJGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNat Rev Endocrinol2012872874222945360
   PubMed Web of Science ®Google Scholar
• LibbyAMFishDNHosokawaPWPatient-level medication regimen complexity across populations with chronic diseaseClin Ther20133538539823541707
   PubMed Web of Science ®Google Scholar
• ThomSPoulterNFieldJEffects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trialJAMA201331091892924002278
   PubMed Web of Science ®Google Scholar
• de KlerkEPatient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorderJ Clin Psychiatry200162Suppl 22434711599648
   PubMed Web of Science ®Google Scholar
• HauberABHanSYangJCEffect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesPatient Prefer Adherence2013793794924086104
   PubMed Web of Science ®Google Scholar
• de VriesSTKeersJCVisserRMedication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetesJ Psychosom Res20147613413824439689
   PubMed Web of Science ®Google Scholar
• ReginsterJYRabendaVNeuprezAAdherence, patient preference and dosing frequency: understanding the relationshipBone2006384 Suppl 1S2616520104
   PubMed Web of Science ®Google Scholar
• BartlRGoetteSHadjiPHammerschmidtTPersistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in GermanyOsteoporos Int200516Suppl 3S45
   Google Scholar
• DowneyTWFoltzSHBoccuzziSJOmarMAKahlerKHAdherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care settingSouth Med J20069957057516800411
   PubMed Web of Science ®Google Scholar
• Penning-van BeestFJErkensJAOlsonMHeringsRMDeterminants of non-compliance with bisphosphonates in women with postmenopausal osteoporosisCurr Med Res Opin2008241337134418380910
   PubMed Web of Science ®Google Scholar
• DoggrellSExenatide extended-release; clinical trials, patient preference, and economic considerationsPatient Prefer Adherence20137354523341736
   PubMed Web of Science ®Google Scholar
• BestJHBoyeKSRubinRRCaoDKimTHPeyrotMImproved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice dailyDiabet Med20092672272819573122
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacConellLEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet201037643143920580422
   PubMed Web of Science ®Google Scholar
• Questionnaire: BrodMSkovlundSEWittrup-JensenKUMeasuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experienceQual Life Res200615348149116547787
   PubMed Web of Science ®Google Scholar
• MohamedAFZhangJJohnsonFRAvoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferencesDiabetes Metab20133939740323880594
   PubMedGoogle Scholar